Balyasny Asset Management LLC Savara Inc Transaction History

Balyasny Asset Management LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$3.66 - $5.34 $101,868 - $148,628	27,833 New	27,833 $112,000
Q1 2023 May 15, 2023	BUY	$1.6 - $2.82 $46,390 - $81,763	28,994 New	28,994 $56,000
Q2 2021 Aug 16, 2021	SELL	$1.51 - $2.29 $17,383 - $26,362	-11,512 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$1.17 - $2.33 $13,469 - $26,822	11,512 New	11,512 $24,000

128

158M

67.6K

29.4K

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $365M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.